Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Inclusion Criteria:

• Histologically or cytologically confirmed, locally advanced or metastatic NSCLCpatients, who is not suitable for surgery or radiotherapy
• Evaluable or measurable disease per Response Evaluation Criteria in SolidTumors(RECIST1.1)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Life expectancy ≥12 weeks
• Must have evidence of positive c-Met protein expression by IHC from either local dataor the results of molecular pre-screening evaluations；Must haved evidence of MET exon 14 skipping alterations in blood and/or tissue samples.
• Adequate bone marrow, hepatic, and renal function
• Patients of child bearing potential must agree to take contraception during the studyand for 3 months after the last day of treatment
• Signed Informed Consent Form

Exclusion Criteria:

• Prior or current treatment with the type II of c-MET inhibitor or HGF/c-Met antibodytherapy
• Confirmed ALK or ROS1 rearrangement
• Prior treatment with targeting agents (Including EGFR tyrosine kinase inhibitors,VEGFRTKIs,the tpye I of MET TKIs, etc.) within 14 days or 5 half-life
• Prior treatment with anticancer agents (Including cytotoxic chemotherapy,radiotherapy,immunotherapy etc.) within 4 weeks
• Brain/meninges metastases unless asymptomatic, stable and not requiring steroids formaintenance
• History of interstitial lung disease, drug-induced interstitial lung disease,radiation pneumonitis which required steroid treatment, or any evidence of clinicallyactive interstitial lung disease, radiological documentation of idiopathic pulmonaryfibrosis at baseline; uncontrolled pleural effusion/pericardial effusion
• Any evidence of severe or uncontrolled systemic diseases, including CTCAE 2 or higheractive infection, unstable angina pectoris, congestive cardiac failure and severeliver/renal or metabolic disease
• Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
• History of organ transplant; had surgery or severe injury within 4 weeks
• Uncontrolled hypertension（Systolic blood pressure≥160mmHg and/or diastolic bloodpressure≥100mmHg ）
• Patients unable to swallow orally administered medication, prior surgical proceduresaffecting absorption.
• Pregnant (positive pregnancy test) or lactating women